Imugene highlights azer-cel progress as trial patient enters remission
Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) is drawing fresh attention to its experimental cancer therapy azer-cel after a Channel 10 news report highlighted a patient who entered remission following treatment in the company’s clinical trial. The report …